ARCUTIS BIOTHERAPEUTICS, INC. Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration of $3.50 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Alternative
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $3.50M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $3.50M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $3.50M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $3.50M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration |
|---|---|
| 2025-12-31 | $3.50M 10-K · filed 2026-02-25 |
| 2024-12-31 | $3.50M 10-K · filed 2025-02-25 |
| 2023-12-31 | $3.50M 10-K · filed 2024-02-27 |
| 2022-12-31 | $3.50M 10-K · filed 2023-02-28 |
| 2021-12-31 | $3.50M 10-K · filed 2022-02-22 |
| 2020-12-31 | $3.50M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |